We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

HORIBA Acquires MedTest Dx and Pointe Scientific to Expand Laboratory Chemistry Offerings

By LabMedica International staff writers
Posted on 03 Feb 2021
HORIBA, Ltd. (Kyoto, Japan) has acquired MedTest Holdings, Inc. (Canton, MI, USA), composed of MedTest Dx, Inc., Pointe Scientific, Inc., Clinitox Diagnostix, Inc., and Medical Laboratory Solutions, Inc.).

HORIBA Medical provides an extensive and complete line of hematology and clinical chemistry analyzers (including reagents) for use in In-vitro Diagnostics. MedTest Dx manufactures chemistry reagents and offers diagnostic solutions for decentralized clinical testing, providing a combination of screening instruments and reagent manufacturing in medical technologies, with a wide portfolio of products for IVD testing laboratories. The acquisition will combine the complimentary innovative technology offerings of HORIBA Medical with MedTest Dx technology, Clinitox, and Pointe Scientific's R&D and manufacturing capabilities, with particular expertise in FDA 510K and CLIA clearances, to address the multidisciplinary requirements of IVD1 testing customers.

Illustration
Illustration

"Our long term vision and continuous investments coupled with our outstanding employees have resulted in pursuing innovative Chemistry and Immunochemistry technology solutions. I am extremely pleased that this long term vision has resulted in acquiring MedTest," said Mr. Atsushi Horiba, Chairman & Group CEO of HORIBA, Ltd.

"This acquisition provides HORIBA Medical the opportunity to address the IVD market's multidisciplinary requirements along with the complimentary innovative technology of Pointe Scientific and MedTest's high quality Chemistry solutions. HORIBA Medical will continue offering innovative technology solutions through its Yumizen2 brand and current distribution channels," said HORIBA Medical segment leader Dr. Jai Hakhu, Chairman and CEO of HORIBA Instruments Incorporated and President of HORIBA ABX SAS in France.

Related Links:
HORIBA, Ltd.
MedTest Holdings, Inc.



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
New
HPV Test
Allplex HPV28 Detection
New
Hematology Consumables
Bioblood Devices

Latest Industry News

Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
03 Feb 2021  |   Industry

FDA Clears Blood-Based Companion Diagnostic for Advanced Breast Cancer Therapy
03 Feb 2021  |   Industry

CareDx Expands Precision Oncology Portfolio with Naveris Acquisition
03 Feb 2021  |   Industry



ADLM